Sanofi (SNY) announced that people with early type 2 diabetes uncontrolled on metformin showed superior HbA1c - glycated hemoglobin - reduction with Lantus versus sitagliptin. The company reported presentation of these data from the EASIE study at the American Diabetes Association 72nd Scientific Sessions.
The company stated that about 50 percent more patients on Lantus achieved target HbA1c versus sitagliptin at study endpoint.
Pierre Chancel, Senior Vice President, Global Diabetes, Sanofi, said, "The EASIE study adds valuable data to further strengthen the efficacy profile of Lantus when initiated early in the treatment pathway after metformin,"
For comments and feedback: editorial@rttnews.com